Clinical study according to pathogenesis treatment for psoriasis vulgaris

Conditions

psoriasis

Liming Lu, Meiling Xuan, Yuhong Yan, Li Geng, Li Zhou et al. (7 authors)

Trials2016-10-032 citations

Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.

Yao DN, Lu CJ, Wen ZH, Yan YH, Xuan ML, Li XY, Li G, He ZH, Xie XL, Deng JW, Guo XF, Ou AH.

2016-03-1614 citations

10.1186/s13063-016-1272-x

Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial.

Wen ZH, Xuan ML, Yan YH, Li XY, Yao DN, Li G, Guo XF, Ou AH, Lu CJ.

2014-07-2212 citations

10.1186/1745-6215-15-294

Interventions

Intervention group:PSORI-CM 01 granules+ Calcipotriol Betamethasone and Calcipotriol Ointment

Control group:Placebo granules + Calcipotriol Betamethasone and Calcipotriol Ointment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 65 years old, male or female patients; (2) stationary stage, PASI> 10 or BSA > 10, meanwhile PASI<30 and BSA<30; (3) Infrom censent.

Exclusion criteria

Exclusion criteria: (1) Guttate psoriasis, inverse psoriasis or exclusively involves the face; (2) Pregnant, lactating, or which one plan to become pregnant in a year; (3) SAS more than 50 or SDS more than 53, or with other psychiatric disorders; (4) With history of cardiovascular, respiratory, digestive, urinary, and hematologic disease, which can't controlled through common treatment. Either with cancer, infection, electrolyte imbalance, acid-base disturbance and calcium metabolic disorder; (5) Allergic to any medicine or ingredients used in this study; (6) Participating other clinical trials or participated within 1 month; (7) Topical treatments (i.e. corticosteroids, Retinoic acid) within 2 weeks; systemic therapy or phototherapy (UVB and PUVA) within 4 weeks; biological therapy within 12 weeks; (8) Acute progression of psoriasis, and erythroderma tendency; (9) Patients need systemic treatment prescribed by doctors.

Design outcomes

Primary

Measure	Time frame
Relapse rate in treatment period / follow-up period;Psoriasis Area and Severity Index score;	—

Secondary

Measure	Time frame
Relapse time interval;Onset time;Rebound rate;Cumulative consumption of medicine;Visual Analogue Scale;the Body Surface Area;the Dermatology Quality Life Index;SF-36 health survey;	—

Countries

China

Contacts

Public ContactLu Chuanjian

luchuanjian888@vip.sina.com+86 13822250116

Outcome results

None listed